H A Vargas1, I A Burger2, D A Goldman3, M Miccò2, R E Sosa2, W Weber2, D S Chi4, H Hricak2, E Sala2. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Av, room C278, New York, NY, 10065, USA. vargasah@mskcc.org. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Av, room C278, New York, NY, 10065, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Av, New York, NY, 10065, USA. 4. Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Av, New York, NY, 10065, USA.
Abstract
OBJECTIVE: Our aim was to evaluate the associations between quantitative (18)F-fluorodeoxyglucose positron-emission tomography (FDG-PET) uptake metrics, optimal debulking (OD) and progression-free survival (PFS) in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. METHODS: Fifty-five patients with recurrent ovarian cancer underwent FDG-PET/CT within 90 days prior to surgery. Standardized uptake values (SUVmax), metabolically active tumour volumes (MTV), and total lesion glycolysis (TLG) were measured on PET. Exact logistic regression, Kaplan-Meier curves and the log-rank test were used to assess associations between imaging metrics, OD and PFS. RESULTS: MTV (p = 0.0025) and TLG (p = 0.0043) were associated with OD; however, there was no significant association between SUVmax and debulking status (p = 0.83). Patients with an MTV above 7.52 mL and/or a TLG above 35.94 g had significantly shorter PFS (p = 0.0191 for MTV and p = 0.0069 for TLG). SUVmax was not significantly related to PFS (p = 0.10). PFS estimates at 3.5 years after surgery were 0.42 for patients with an MTV ≤ 7.52 mL and 0.19 for patients with an MTV > 7.52 mL; 0.46 for patients with a TLG ≤ 35.94 g and 0.15 for patients with a TLG > 35.94 g. CONCLUSION: FDG-PET metrics that reflect metabolic tumour burden are associated with optimal secondary cytoreductive surgery and progression-free survival in patients with recurrent ovarian cancer. KEY POINTS: • Both TLG and MTV were associated with optimal tumour debulking. • There was no significant association between SUVmax and tumour debulking status. • Patients with higher MTV and/or TLG had significantly shorter PFS. • SUVmax was not significantly related to PFS.
OBJECTIVE: Our aim was to evaluate the associations between quantitative (18)F-fluorodeoxyglucose positron-emission tomography (FDG-PET) uptake metrics, optimal debulking (OD) and progression-free survival (PFS) in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. METHODS: Fifty-five patients with recurrent ovarian cancer underwent FDG-PET/CT within 90 days prior to surgery. Standardized uptake values (SUVmax), metabolically active tumour volumes (MTV), and total lesion glycolysis (TLG) were measured on PET. Exact logistic regression, Kaplan-Meier curves and the log-rank test were used to assess associations between imaging metrics, OD and PFS. RESULTS:MTV (p = 0.0025) and TLG (p = 0.0043) were associated with OD; however, there was no significant association between SUVmax and debulking status (p = 0.83). Patients with an MTV above 7.52 mL and/or a TLG above 35.94 g had significantly shorter PFS (p = 0.0191 for MTV and p = 0.0069 for TLG). SUVmax was not significantly related to PFS (p = 0.10). PFS estimates at 3.5 years after surgery were 0.42 for patients with an MTV ≤ 7.52 mL and 0.19 for patients with an MTV > 7.52 mL; 0.46 for patients with a TLG ≤ 35.94 g and 0.15 for patients with a TLG > 35.94 g. CONCLUSION:FDG-PET metrics that reflect metabolic tumour burden are associated with optimal secondary cytoreductive surgery and progression-free survival in patients with recurrent ovarian cancer. KEY POINTS: • Both TLG and MTV were associated with optimal tumour debulking. • There was no significant association between SUVmax and tumour debulking status. • Patients with higher MTV and/or TLG had significantly shorter PFS. • SUVmax was not significantly related to PFS.
Authors: Philipp Harter; Jalid Sehouli; Alexander Reuss; Annette Hasenburg; Giovanni Scambia; David Cibula; Sven Mahner; Ignace Vergote; Alexander Reinthaller; Alexander Burges; Lars Hanker; Martin Pölcher; Christian Kurzeder; Ulrich Canzler; Karl Ulrich Petry; Andreas Obermair; Edgar Petru; Barbara Schmalfeldt; Domenica Lorusso; Andreas du Bois Journal: Int J Gynecol Cancer Date: 2011-02 Impact factor: 3.437
Authors: Michael Friedlander; Edward Trimble; Anna Tinker; David Alberts; Elisabeth Avall-Lundqvist; Mark Brady; Philipp Harter; Sandro Pignata; Eric Pujade-Lauraine; Jalid Sehouli; Ignace Vergote; Philip Beale; Rudd Bekkers; Paula Calvert; Lawrence Copeland; Ros Glasspool; Antonio Gonzalez-Martin; Dionysis Katsaros; Jae Won Kim; Brigitte Miller; Diane Provencher; Lawrence Rubinstein; Mostafa Atri; Alain Zeimet; Monica Bacon; Henry Kitchener; Gavin C E Stuart Journal: Int J Gynecol Cancer Date: 2011-05 Impact factor: 3.437
Authors: Stephanie Nougaret; Yulia Lakhman; Mithat Gönen; Debra A Goldman; Maura Miccò; Melvin D'Anastasi; Sarah A Johnson; Krishna Juluru; Angela G Arnold; Ramon E Sosa; Robert A Soslow; Hebert Alberto Vargas; Hedvig Hricak; Noah D Kauff; Evis Sala Journal: Radiology Date: 2017-06-16 Impact factor: 11.105
Authors: N L Robertson; H Hricak; Y Sonoda; R E Sosa; M Benz; G Lyons; N R Abu-Rustum; E Sala; H A Vargas Journal: Gynecol Oncol Date: 2016-01-11 Impact factor: 5.482
Authors: Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2021-07-03 Impact factor: 9.236
Authors: Irene A Burger; Ruben Casanova; Seraina Steiger; Lars Husmann; Paul Stolzmann; Martin W Huellner; Alessandra Curioni; Sven Hillinger; C Ross Schmidtlein; Alex Soltermann Journal: J Nucl Med Date: 2016-01-28 Impact factor: 10.057
Authors: Christine A Parkinson; Davina Gale; Anna M Piskorz; Heather Biggs; Charlotte Hodgkin; Helen Addley; Sue Freeman; Penelope Moyle; Evis Sala; Karen Sayal; Karen Hosking; Ioannis Gounaris; Mercedes Jimenez-Linan; Helena M Earl; Wendi Qian; Nitzan Rosenfeld; James D Brenton Journal: PLoS Med Date: 2016-12-20 Impact factor: 11.069